Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT07545122 trial (CT-202): what clinicians have said so far
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
- NCT07545122 ↗
- Recruiting
- Context Therapeutics Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT07545122 (CT-202 in recurring triple negative breast, colorectal and urothelial cancers) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT07545122 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Urothelial Cancer
- Interventions
- CT-202
- Arms
- Phase 1a · Experimental
- Phase 1b · Experimental
- Enrollment
- 162 (estimated)
- Primary outcomes
- Phase 1a: Incidence of Dose Limiting Toxicities (DLTs)
- Phase 1b: Overall response rate (ORR)
- Sponsor
- Context Therapeutics Inc.
- Start
- Sep 3, 2026
- Primary completion
- Jan 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07545122 · updated Nov 16, 2026